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Key points: 
• Hif-1α is dispensable for cell-autonomous HSC survival 
• HSCs do not require intrinsic Hif-1α to respond to haematopoietic injury 
 
	
Abstract 
The haematopoietic stem cell (HSC) pool is maintained under hypoxic conditions within the bone 
marrow (BM) microenvironment. Cellular responses to hypoxia are largely mediated by hypoxia-
inducible factors, Hif-1 and Hif-2. The oxygen-regulated alpha subunits of Hif-1 and Hif-2 (namely, 
Hif-1α and Hif-2α) form dimers with their stably expressed beta subunits, and control 
the transcription of downstream hypoxia-responsive genes to facilitate adaptation to low oxygen 
tension. An initial study concluded that Hif-1α is essential for HSC maintenance, whereby Hif-1α-
deficient HSCs lost their ability to self-renew in serial transplantation assays. In another study, we 
demonstrated that Hif-2α is dispensable for cell-autonomous HSC maintenance, both under 
steady-state conditions and following transplantation.  Given these unexpected findings, we set out 
to revisit the role of Hif-1α in cell-autonomous HSC functions. Here we demonstrate that inducible 
acute deletion of Hif-1α has no impact on HSC survival. Notably, unstressed HSCs lacking Hif-1α 
efficiently self-renew and sustain long-term multilineage haematopoiesis upon serial 
transplantation. Finally, Hif-1α-deficient HSCs recover normally after hematopoietic injury induced 
by serial administration of 5-fluorouracil. We therefore conclude that despite the hypoxic nature of 
the BM microenvironment, Hif-1α is dispensable for cell-autonomous HSC maintenance.  
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Introduction 
Haematopoietic stem cells (HSCs) reside in hypoxic bone marrow (BM) niches where they self-
renew and sustain life-long multilineage haematopoiesis1-3. Cellular responses to hypoxia are 
predominantly mediated by hypoxia-inducible factors, Hif-1 and Hif-2 that facilitate the transcription 
of hypoxia-responsive genes. Several studies employed a conditional gene knockout strategy to 
determine the role of Hif-1α and Hif-2α in HSC functions4,5. An initial study concluded that inducible 
Hif-1α deletion from the mouse haematopoietic system results in the progressive loss of HSCs 
upon serial transplantation4, indicating that Hif-1α is required for HSC maintenance4. We 
demonstrated that constitutive or inducible haematopoiesis-specific Hif-2α deletion did not affect 
HSC maintenance5.  Surprisingly, co-deletion of Hif-1α and Hif-2α had no impact on HSC numbers, 
steady-state haematopoiesis nor reconstitution upon transplantation5. These unexpected findings 
gave rise to the hypothesis that Hif-1α may not be as essential for HSC maintenance as previously 
suggested4. Here, using serial transplantation assays, we demonstrate that unstressed HSCs do 
not critically require Hif-1α to survive and self-renew. 
 
Materials and Methods 
Mice. Hif-1αfl/fl, Mx1-Cre and Vav-iCre mice have been described previously6-8 and were of 
C57BL/6 genetic background. Sex-matched 8 to 12 week old mice were used. Animal experiments 
were authorised by UK Home Office.   
               
FACS analysis. Analysis and sorting was done using BD LSRFortessa™ cell analyzer and BD 
FACSAriaII cell sorter. Antibodies (Suppl. Table 1) were used as described previously9-11. 
Representative gating is shown in Suppl. Fig. 1.  
 
Transplantation assays. 500,000 CD45.2+ test donor unfractionated BM cells were injected 
intravenously into lethally irradiated (10 Gy) CD45.1+/CD45.2+ congenic recipients alongside 
500,000 CD45.1+ competitor unfractionated BM cells. Conditional gene deletion was achieved by 
administration of six intraperitoneal pIpC injections over the period of 10 days, every other day (GE 
Healthcare; 0.3 mg per dose).  For LSK cell transplantation assays, 3,000 LSK cells sorted from 
donor BM were transplanted together with 200,000 CD45.1+ unfractionated BM cells.  
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Statistical analysis. Statistical significance was determined using Mann-Whitney or Mantel-Cox 
tests. 
 
Results and Discussion 
We acutely deleted Hif-1α specifically within the haematopoietic system using Mx1-Cre5,9 (Fig. 1A). 
Given that Mx1-Cre recombines within the haematopoietic system, BM microenvironment and 
extramedullary tissues7,12, we first transplanted unfractionated BM from untreated CD45.2+ Hif-
1αfl/fl;Mx1-Cre and control (Hif-1α+/+ without Mx1-Cre or Hif-1αfl/fl without Mx1-Cre) mice into wild-
type (WT) lethally irradiated syngeneic recipients (Fig. 1A). Following reconstitution (Fig. 1B), 
recipients received pIpC 8 weeks after transplantation, and were analysed 2 weeks later. 
Peripheral blood (PB) analyses of the pIpC-treated recipients revealed that deletion of Hif-1α (Fig. 
1C) had no impact on CD45.2+ donor-derived chimerism (Fig. 1D) and multilineage 
haematopoiesis in the BM (Fig. 1E), and spleen (Suppl. Fig. 2). The contribution of donor-derived 
cells to Lin–Sca-1–c-Kit+ (LK), Lin–Sca-1+c-Kit+ (LSK), LSKCD48−CD150+ HSC, LSKCD48−CD150− 
multipotent progenitor (MPP), LSKCD48+CD150− haematopoietic progenitor cell-1 (HPC-1) and 
LSKCD48+CD150+ HPC-2 compartments was also comparable (Fig. 1F-G). Therefore, acute 
deletion of Hif-1α has no immediate impact on HSC survival and multilineage haematopoiesis.  
 
To test the self-renewal capacity of Hif-1α-deficient (Hif-1αΔ/Δ) HSCs we performed competitive 
serial transplantation assays with sorted CD45.2+LSK cells from primary recipients 2 weeks after 
pIpC treatment (Fig. 1A). LSK cells from primary recipients efficiently reconstituted short-term and 
long-term haematopoiesis in secondary recipients (Fig. 1H). 16 weeks after transplantation, 
sustained Hif-1α deletion was confirmed (Fig. 1I), and Hif-1αΔ/Δ LSK cells efficiently contributed to 
all differentiated lineages in the BM and spleen (Fig. 1J and Suppl. Fig. 3), and LK, LSK, HSC, 
MPP, and HPC BM compartments of the secondary recipient mice (Fig. 1K-L). Finally, sorted Hif-
1αΔ/Δ LSK cells from secondary recipients (16 weeks after secondary transplantation) successfully 
reconstituted long-term multilineage haematopoiesis in tertiary recipients (Fig. 1M-N). Complete 
Hif-1α deletion was maintained for the duration of these experiments (Fig. 1O). Therefore, self-
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renewing long-term HSCs do not critically require Hif-1α to maintain their pool upon the stress of 
serial transplantation.  
 
To test the cell-autonomous role of Hif-1α in HSC stress responses, we employed Hif-1αfl/fl;Vav-
iCre mice in which Hif-1α is conditionally deleted specifically from haematopoietic cells using a 
codon-improved Cre (iCre)5,8. Hif-1αfl/fl;Vav-iCre and control mice received 3 doses of 5-fluorouracil 
(5-FU) and were analysed 10 days after the last 5-FU administration (Fig. 1P). We also analysed 
untreated Hif-1αfl/fl;Vav-iCre and control mice that did not receive 5-FU. While 5-FU-treated mice 
had decreased survival compared to untreated mice, we observed no differences in survival 
between 5-FU-treated Hif-1αfl/fl;Vav-iCre and control mice (Fig. 1Q). 5-FU-treated Hif-1αfl/fl;Vav-iCre 
and control mice had comparable total BM cellularity, and BM LSK, HSC and LK cell numbers (Fig. 
1R). Thus Hif-1α is not essential for cell-autonomous HSC maintenance following serial 5-FU 
administration.  
 
We next determined the long-term consequences of Hif-1α deletion from the haematopoietic 
system. We transplanted unfractionated BM cells from untreated Hif-1αfl/fl;Mx1-Cre or control mice, 
administered pIpC and analysed the primary recipients 32 weeks after pIpC treatment (Fig. 2A). 
PB and BM analyses indicated that loss of Hif-1α did not affect long-term multilineage 
haematopoiesis (Fig. 2B-C), or donor-derived chimerism in the stem and progenitor cell 
compartments of the BM (Fig. 2D-E) and spleens (data not shown) of the recipient mice 32 weeks 
after pIpC treatment. Moreover, LSK cells of both genotypes equally reconstituted long-term 
multilineage haematopoiesis in secondary recipients (Fig. 2F-G) and evenly contributed to the 
stem and progenitor cell compartments of the recipients (Fig. 2H). Efficient Hif-1α deletion was 
confirmed by PCR on genomic DNA from donor-derived cells (Fig. 2I). Given that donor-derived 
HSCs in this experiment have undergone long-term stress and are very rare in secondary 
recipients, to perform tertiary transplantation assays, instead of re-transplanting purified LSK cells 
we transplanted unfractionated BM cells harvested from secondary recipients 16 weeks post 
transplantation. BM cells of both genotypes equally generated multilineage haematopoiesis in 
tertiary recipients (Fig. 2J-K). Efficient Hif-1α gene deletion was maintained for the duration of the 
serial transplantation experiment (Fig. 2L). Thus, HSCs with chronic Hif-1α deficiency sustain 
	 6 
normal steady-state multilineage haematopoiesis and display normal regenerative capacity upon 
serial transplantation.  
 
Finally, we set out to delete Hif-1α more broadly from the BM using Mx1-Cre, which in addition to 
haematopoietic cells, also recombines in the BM microenvironment13. Hif-1αfl/fl;Mx1-Cre and control 
mice received 6 doses of pIpC and were analysed 30 days after the last injection (Suppl. Fig.  4A). 
pIpC-treated Hif-1αfl/fl;Mx1-Cre and control mice had comparable numbers of nucleated BM cells, 
LSK cells, and HSC, MPP, HPC-1 and HPC-2 populations (Suppl. Fig. 4B). We next treated Hif-
1αfl/fl;Mx1-Cre and control mice with 6 doses of pIpC followed by 2 doses of 5-FU (Suppl. Fig. 4C).  
We found that a combined stress of pIpC treatment and subsequent 5-FU administration resulted 
in substantially decreased survival of these mice (Suppl. Fig. 4D). Importantly however, there was 
no difference in survival of pIpC- and 5-FU-treated Hif-1αfl/fl;Mx1-Cre and control mice. Therefore, 
Mx1-Cre-mediated deletion of Hif-1α had no impact on HSC numbers or their ability to respond to 
5-FU. 
 
HSCs are constantly exposed to local hypoxia within the BM14,15 and the low oxygen tension has 
been proposed to protect HSCs16. Takubo et al.4 found a defect in HSC self-renewal upon Hif-1α 
deletion and suggested that Hif-1α is an important mediator of HSC functions. Here we set out to 
acutely induce deletion of Hif-1α in the haematopoietic system and determine its short-term and 
long-term impact on HSC maintenance. We found that inactivation of Hif-1α did not compromise 
survival of HSCs 2 weeks after gene ablation and unstressed Hif-1αΔ/Δ HSCs self-renewed equally 
efficiently compared to control counterparts upon serial transplantation. Furthermore, deletion of 
Hif-1α had no long-term consequences for maintenance of unstressed HSCs within 32 weeks after 
pIpC administration and did not compromise their ability to repopulate recipient mice upon serial 
transplantation. Different conclusions from our study and that of Takubo et al. may result from 
discrepancies in experimental designs. While they serially transplanted LSK cells from pIpC-
treated Hif-1αfl/fl;Mx1-Cre mice, we conducted our serial transplantation assays using Hif-1αΔ/Δ LSK 
cells sorted from pIpC-treated WT chimeric recipient mice harbouring Hif-1αfl/fl;Mx1-Cre BM cells. 
Given that Mx1-Cre recombines also within the BM microenvironment12 and that Hif-1α is required 
for BM mesenchymal progenitor cell functions17, Hif-1α deletion from the BM microenvironment 
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may have affected HSC functions, thus contributing to the phenotypes observed by Takubo et al. 
Finally, to test the cell-autonomous role of Hif-1α in ageing, Takubo et al. transplanted Hif-
1αfl/fl;Mx1-Cre BM cells into recipient mice and administered pIpC 4 months later. While they did 
not observe any differences 4 months after pIpC treatment, 11 months after pIpC treatment they 
found that the level of repopulation by Hif-1α-deficient BM cells was decreased. This raises a 
possibility that the cell-autonomous Hif-1α deficiency causes HSC defects only when exposed to 
an ageing BM microenvironment.  
 
In conclusion, our data presented here, taken together with our previous findings that Hif-2α is 
dispensable for HSC maintenance5, suggest that hypoxia impacts on HSC functions in a Hif-1- and 
Hif-2-independent manner. We conclude that despite the hypoxic nature of the BM 
microenvironment, self-renewing HSCs do not critically require intrinsic Hif-1α to maintain their 
pool and sustain long-term multilineage haematopoiesis.  
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Figure Legends 
Figure 1. Haematopoiesis-specific deletion of Hif-1α does not affect HSC survival and 
maintenance, and their ability to respond to 5-FU-induced stress. (A) Experimental design. 
500,000 donor-derived (CD45.2+) unfractionated BM cells from untreated Hif-1αfl/fl;Mx1-Cre and 
control (without Mx1-Cre) mice were transplanted into lethally irradiated syngeneic 
CD45.1+/CD45.2+ recipient mice (together with 500,000 CD45.1+ competitor BM cells). Two 
independent donors were used per genotype. 8 weeks post-transplantation, the mice received 6 
sequential doses of pIpC over a period of 10 days (every alternate day) and were analysed 2 
weeks after last dose of pIpC. CD45.2+ LSK cells from the primary recipients were serially 
transplanted into secondary and tertiary recipients. (B) Percentage of CD45.2+ donor-derived cells 
8 weeks post-transplantation in the peripheral blood (PB) of primary recipient mice prior to pIpC 
treatment (n=5-6 per group). (C) Representative gel showing PCR amplification of genomic DNA 
from donor-derived CD45.2+ fraction of the PB of pIpC-treated recipient mice 2 weeks after last 
pIpC injection. WT – wild-type allele, Δ – excised allele, fl – undeleted conditional allele. For PCR 
controls we used genomic DNA from c-Kit+ cells from BM of Hif-1α+/+, Hif-1αfl/fl and Hif-1αfl/fl;Vav-
iCre mice. (D) Percentage of CD45.2+ donor-derived cells in PB 2 weeks after the last pIpC 
injection (n=5-6 per group). (E) Percentage of CD45.2+ cells in the unfractionated BM (total BM 
cells), and myeloid (CD11b+Gr1+), B lymphoid (CD19+B220+) and erythroid (Ter119+) cell 
compartments of the primary recipient mice. Data are mean ± SEM (n=5-6 per group). (F) 
Percentage of CD45.2+ donor-derived cells measured in BM Lin−Sca-1−c-Kit+ (LK) and Lin−c-
Kit+Sca-1+ (LSK) cell compartments of the primary recipients. Data are mean ± SEM (n=5-6 per 
group). (G) Percentage of CD45.2+ donor-derived cells in LSK CD48−CD150+ HSC, LSK 
CD48−CD150− MPP, and primitive progenitor (LSK CD48+CD150− HPC-1 and LSK CD48+CD150+ 
HPC-2) cell compartments of primary recipients. Data are mean ± SEM (n=5-6 per group). (H) PB 
chimerism in secondary recipients of control and Hif-1α∆/∆ LSK cells sorted from BM of the primary 
recipients. Data are mean ± SEM (n=6 per group). (I) Representative gel showing efficient deletion 
of the conditional alleles of Hif-1α in the CD45.2+ BM cells of secondary recipients 16 weeks after 
transplantation. For PCR controls we used genomic DNA from c-Kit+ cells from BM of Hif-1α+/+, Hif-
1αfl/fl and Hif-1αfl/fl;Vav-iCre mice. (J) Percentage of CD45.2+ cells in total BM, myeloid, B lymphoid, 
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and erythroid cell compartments of the secondary recipient mice 16 weeks post-transplantation. 
Data are mean ± SEM (n=6 per group). (K-L) Percentage of CD45.2+ cells in BM stem and 
progenitor cell compartments of the secondary recipient mice 16 weeks post-transplantation. Data 
are mean ± SEM (n=6 per group). (M) Results of the tertiary transplantation assay. The graph 
shows the percentage of tertiary recipients with long-term multilineage reconstitution (>0.5% of 
donor-derived myeloid and lymphoid cells in BM) 16 weeks after tertiary transplantation of Hif-1α∆/∆ 
and control LSK cells sorted from BM of the secondary recipients. Data are mean ± SEM (n=12-19 
per group) (N) Percentage of CD45.2+ cells in the BM haematopoietic compartments of tertiary 
recipient mice 16 weeks after transplantation (n=12-19 per group). (O) Representative gel showing 
efficient deletion of the conditional alleles of Hif-1α in the CD45.2+ BM cells of tertiary recipients 16 
weeks after transplantation. For PCR controls we used genomic DNA from c-Kit+ cells from BM of 
Hif-1α+/+, Hif-1αfl/fl and Hif-1αfl/fl;Vav-iCre  mice. (P) Experimental design. Hif-1αfl/fl;Vav-iCre and 
control mice received 3 sequential doses of 5-FU (150 mg/kg; 10 days apart) and were analysed 
10 days after the last 5-FU administration. In parallel, untreated Hif-1αfl/fl;Vav-iCre and control mice 
that did not receive 5-FU were also analysed. (Q) Kaplan-Meier survival curve of Hif-1αfl/fl;Vav-iCre 
and control mice treated with 5-FU (i.e. +5-FU) (n=7-8 per group) or those that were not treated 
with 5-FU (i.e. -5-FU) (n=4-6 per group). Arrows in the graph indicate 5-FU administration. (R) 
Total numbers (per 2 femurs and 2 tibias) of BM white blood cells, LSK cells, HSCs and LK cells 
from the mice described in Fig. 1P-Q. Data are mean ± SEM (n=4-6 per group). At least two 
independent experiments were performed for all analyses.  
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Figure 2. Prolonged Hif-1α deficiency does not affect the steady-state maintenance of HSCs 
and their regenerative capacity.  
(A) Experimental design. Primary recipient mice were transplanted with 500,000 donor-derived 
unfractionated BM cells from untreated Hif-1αfl/fl;Mx1-Cre and control mice (together with 500,000 
CD45.1+ competitor BM cells). 8 weeks post-transplantation, the mice received 6 doses of pIpC. 
The mice were analysed 32 weeks after the last dose of pIpC. CD45.2+ LSK cells from the primary 
recipients were transplanted into secondary recipients. 2x106 total BM cells from secondary 
recipients were transplanted into tertiary recipients together with 200,000 CD45.1+ unfractionated 
BM cells. (B) CD45.2+ donor-derived PB chimerism 20, 24, 28 and 32 weeks after the last dose of 
pIpC. Mean ± SEM (n=5-7 per group). (C) Percentage of CD45.2+ cells in total BM, myeloid, B 
lymphoid, and erythroid cell compartments of primary recipients 32 weeks after pIpC treatment. 
Data are mean ± SEM (n=5-7 per group). (D-E) Percentage of CD45.2+ cells in the indicated 
haematopoietic compartments of the primary recipients. Data are mean ± SEM (n=5-7 per group). 
(F) LSK cells of indicated genotypes were pooled from primary recipients 32 weeks after pIpC 
treatment and transplanted into secondary recipients. The graph shows CD45.2+ donor-derived PB 
chimerism in secondary recipient mice 4, 12 and 16 weeks after transplantation. Data are mean ± 
SEM (n=4-7 per group). (G) CD45.2+ donor-derived chimerism within the total BM cell fraction, and 
myeloid, B lymphoid and erythroid cell compartments of secondary recipient mice 16 weeks after 
transplantation. Data are mean ± SEM (n=4-7 per group). (H) Percentage of CD45.2+ cells in the 
indicated haematopoietic stem and progenitor cell compartments of the secondary recipients. 
Mean ± SEM (n=4-7 per group). (I) PCR amplification of genomic DNA from donor-derived 
CD45.2+ cell fraction of the PB of secondary recipient mice 12 weeks post-transplantation. For 
PCR controls we used genomic DNA from c-Kit+ cells from BM of Hif-1α+/+, Hif-1αfl/fl and Hif-
1αfl/fl;Vav-iCre mice. (J) Results of the tertiary transplantation assays. The graph depicts the 
percentage of tertiary recipients with long-term multilineage reconstitution (>0.5% of donor-derived 
myeloid and lymphoid cells in PB) 16 weeks after tertiary transplantation of 2x106 total BM cells 
obtained from the secondary recipients (n=5-10 per genotype). (K) Percentage of CD45.2+ cells in 
white blood cell (total) compartment, and myeloid, B lymphoid, and T lymphoid cell compartments 
of PB in tertiary recipients 16 weeks after transplantation. Data are mean ± SEM (n=5-10 per 
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group). (L) Hif-1α gene deletion was confirmed by PCR on genomic DNA from donor-derived 
CD45.2+ cell fraction of the BM of tertiary recipients 16 weeks post-transplantation. For PCR 
controls we used genomic DNA from c-Kit+ cells from BM of Hif-1α+/+, Hif-1αfl/fl and Hif-1αfl/fl;Vav-
iCre mice. At least two independent experiments were performed for all analyses. 
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Antibody Conjugate Catalog # Clone Manufacturer 
Li
ne
ag
e 
C
oc
kt
ai
l CD4 biotin 553649 H129.19 BD Biosciences 
CD5 biotin 553019 53-7.3 BD Biosciences 
CD8a biotin 553029 53-6.7 BD Biosciences 
CD11b biotin 553309 M1/70 BD Biosciences 
CD45R/B220 biotin 553086 RA3-6B2 BD Biosciences 
Ter119 biotin 553672 TER-119 BD Biosciences 
Gr-1/Ly-6G/C biotin 553125 RB6-8C5 BD Biosciences 
CD45.1 FITC 110706 A20 Biolegend 
Ter119 FITC 116206 TER-119 Biolegend 
CD4 PE 130310 H129.19 Biolegend 
CD45R / B220 PE 103208 RA3-6B2 Biolegend 
CD48 PE 103406 HM48-1 Biolegend 
CD150  PE-Cy7 115914 TC15-12F12.2 Biolegend 
Gr-1/Ly-6G/C PE-Cy7 108416 RB6-8C5 Biolegend 
CD8a APC 100712 53-6.7 Biolegend 
CD11b APC 101212 M1/70 Biolegend 
CD117/c-Kit APC 105812 2B8 Biolegend 
Sca-1/Ly-6A/E APC-Cy7 122513 E13-161.7 Biolegend 
CD19 APC-Cy7 115530 6D5 Biolegend 
CD45.2 Pacific Blue 109820 104 Biolegend 
CD16/CD32 
(FC Block™) None 553142 2.4G2 BD Pharmingen 	
Supplemental Table 1. List of antibodies used for flow cytometry.  
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Supplemental Figure 1.  Representative gating strategy for FACS analyses of 
recipient mice transplanted with BM or LSK cells.  
Total BM cells were first live and size gated using forward scatter area (FSC-A) and 
side scatter area (SSC-A).  Doublets were excluded using FSC-A versus FSC height 
(FSC-H).  Lineage positive cells were excluded by gating on the lineage negative 
(Lin-) population which contains the LK and LSK cells.  LSK cells were further sub-
gated on HSC, MPP, HPC-1, and HPC-2 fractions. Within each population, CD45.2+ 
cells were gated by excluding the bone marrow support (CD45.1+) and recipient-
derived haematopoietic cells remaining after irradiation (CD45.1+/CD45.2+).  
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Supplemental Figure 2. Primary transplantation assay.  
Percentage of CD45.2+ cells in the unfractionated splenocytes (total), and myeloid 
(CD11b+Gr1+), B lymphoid (CD19+B220+), T lymphoid (CD4+ and CD8+) and 
erythroid (Ter119+) cell compartments in spleens of the primary recipient mice. Data 
are mean ± SEM (n=5-6 per group). 				
		
 
Supplemental Figure 3. Secondary transplantation assay.  
CD45.2+ cell chimerism in the indicated spleen cell compartments of the secondary 
recipient mice 16 weeks post-transplantation. Data are mean ± SEM (n=6 per group).  	
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Supplemental Figure 4. Deletion of Hif-1α in Hif-1αfl/fl;Mx1-Cre mice. 
(A) Experimental design. Hif-1αfl/fl;Mx1-Cre and control mice received 6 doses of 
pIpC over a period of 10 days (every alternate day). 30 days after the last pIpC 
treatment mice were analysed. (B) BM analysis of pIpC-treated Hif-1αfl/fl;Mx1-Cre and 
control mice showing total numbers of BM white blood cells, LSK cells, HSCs, MPPs, 
and HPC-1 and HPC-2 populations. Data are mean ± SEM (n=4-5 per group). (C) 
Experimental design. Hif-1αfl/fl;Mx1-Cre and control mice received 6 doses of pIpC 
every alternate day. 14 days after the last pIpC treatment mice were injected with two 
doses of 5-FU, 10 days apart. (D) Kaplan-Meier survival curve of Hif-1αfl/fl;Mx1-Cre  
and control mice treated with both pIpC and 5-FU (n=7-8 per group).  
